Leslie M. Shaw
A5101555764- Alzheimer's disease research and treatments
- Dementia and Cognitive Impairment Research
- Functional Brain Connectivity Studies
- Parkinson's Disease Mechanisms and Treatments
- Advanced Neuroimaging Techniques and Applications
- Renal Transplantation Outcomes and Treatments
- Health, Environment, Cognitive Aging
- Neurological Disease Mechanisms and Treatments
- Amyotrophic Lateral Sclerosis Research
- Bioinformatics and Genomic Networks
- Metabolomics and Mass Spectrometry Studies
- Neuroinflammation and Neurodegeneration Mechanisms
- S100 Proteins and Annexins
- Folate and B Vitamins Research
- Pharmacological Effects and Toxicity Studies
- Antibiotics Pharmacokinetics and Efficacy
- HIV/AIDS drug development and treatment
- Health Systems, Economic Evaluations, Quality of Life
- Neurological disorders and treatments
- Cell Adhesion Molecules Research
- Traumatic Brain Injury and Neurovascular Disturbances
- Hematopoietic Stem Cell Transplantation
- Statistical Methods in Clinical Trials
- Genetic Associations and Epidemiology
- Tryptophan and brain disorders
University of Pennsylvania
2016-2025
California University of Pennsylvania
2017-2025
Northwestern University
2015-2024
Inha University
2024
University of Alabama at Birmingham
2024
Institute for Neurodegenerative Disorders
2010-2024
Philadelphia University
2013-2024
Alzheimer’s Disease Neuroimaging Initiative
2021-2024
Indiana University – Purdue University Indianapolis
2010-2024
University of Iowa
2017-2024
Abstract Objective Develop a cerebrospinal fluid biomarker signature for mild Alzheimer's disease (AD) in Disease Neuroimaging Initiative (ADNI) subjects. Methods Amyloid‐β 1 to 42 peptide (Aβ 1–42 ), total tau (t‐tau), and phosphorylated at the threonine 181 were measured (1) (CSF) samples obtained during baseline evaluation of 100 AD, 196 cognitive impairment, 114 elderly cognitively normal (NC) subjects ADNI; (2) independent 56 autopsy‐confirmed AD cases 52 age‐matched NCs using multiplex...
<b>Background:</b> Neuroimaging measures and chemical biomarkers may be important indices of clinical progression in normal aging mild cognitive impairment (MCI) need to evaluated longitudinally. <b>Objective:</b> To characterize cross-sectionally longitudinally controls, subjects with MCI, Alzheimer disease (AD) enable the assessment utility neuroimaging biomarker measures. <b>Methods:</b> A total 819 (229 cognitively normal, 398 192 AD) were enrolled at baseline followed for 12 months...
Abstract Multifactorial mechanisms underlying late-onset Alzheimer’s disease (LOAD) are poorly characterized from an integrative perspective. Here spatiotemporal alterations in brain amyloid-β deposition, metabolism, vascular, functional activity at rest, structural properties, cognitive integrity and peripheral proteins levels relation to LOAD progression. We analyse over 7,700 images tens of plasma cerebrospinal fluid biomarkers the Disease Neuroimaging Initiative (ADNI). Through a...
Hippocampal volume change over time, measured with MRI, has huge potential as a marker for Alzheimer's disease. The objectives of this study were: (i) to test if constant and accelerated hippocampal loss can be detected in disease, mild cognitive impairment normal ageing short periods, e.g. 6–12 months, MRI the large multicentre setting Disease Neuroimaging Initiative (ADNI); (ii) determine extent which polymorphism apolipoprotein E (ApoE) gene modulates change; (iii) rates correlate...
Abstract Introduction We studied whether fully automated Elecsys cerebrospinal fluid (CSF) immunoassay results were concordant with positron emission tomography (PET) and predicted clinical progression, even cutoffs established in an independent cohort. Methods Cutoffs for amyloid‐β 1–42 (Aβ), total tau/Aβ(1–42), phosphorylated tau/Aβ(1–42) defined against [ 18 F]flutemetamol PET Swedish BioFINDER (n = 277) validated F]florbetapir Alzheimer's Disease Neuroimaging Initiative 646). Clinical...
<b>Objective:</b> A variety of measurements have been individually linked to decline in mild cognitive impairment (MCI), but the identification optimal markers for predicting disease progression remains unresolved. The goal this study was evaluate prognostic ability genetic, CSF, neuroimaging, and obtained same participants. <b>Methods:</b><i>APOE</i> ε4 allele frequency, CSF proteins (Aβ<sub>1-42</sub>, total tau, hyperphosphorylated tau [p-tau<sub>181p</sub>]), glucose metabolism...
Abstract Introduction Increasing evidence suggests a role for the gut microbiome in central nervous system disorders and specific gut‐brain axis neurodegeneration. Bile acids (BAs), products of cholesterol metabolism clearance, are produced liver further metabolized by bacteria. They have major regulatory signaling functions seem dysregulated Alzheimer's disease (AD). Methods Serum levels 15 primary secondary BAs their conjugated forms were measured 1464 subjects including 370 cognitively...
Abstract Objective The Parkinson's Progression Markers Initiative ( PPMI ) is an observational, international study designed to establish biomarker‐defined cohorts and identify clinical, imaging, genetic, biospecimen disease PD progression markers accelerate disease‐modifying therapeutic trials. Methods A total of 423 untreated , 196 Healthy Control HC 64 SWEDD (scans without evidence dopaminergic deficit) subjects were enrolled at 24 sites. To enroll as early possible following diagnosis,...
To test whether plasma tau is altered in Alzheimer disease (AD) and it related to changes cognition, CSF biomarkers of AD pathology (including β-amyloid [Aβ] tau), brain atrophy, metabolism.This was a study prospectively followed patients with (n = 179), mild cognitive impairment 195), healthy controls 189) from the Alzheimer's Disease Neuroimaging Initiative (ADNI) cross-sectionally studied 61), 212), subjective decline 174) 274) Biomarkers for Identifying Neurodegenerative Disorders Early...
<b>Background:</b> PET imaging using [<sup>18</sup>F]fluorodeoxyglucose (FDG) and [<sup>11</sup>C]Pittsburgh compound B (PIB) have been proposed as biomarkers of Alzheimer disease (AD), CSF measures the 42 amino acid β-amyloid protein (Aβ<sub>1-42</sub>) total phosphorylated tau (t-tau p-tau). Relationships between with severity are incompletely understood. <b>Methods:</b> Ten subjects AD, 11 control subjects, 34 mild cognitive impairment from Alzheimer’s Disease Neuroimaging Initiative...
The extent to which large-caliber axonal degeneration contributes Alzheimer disease (AD) progression is unknown. Cerebrospinal fluid (CSF) neurofilament light (NFL) concentration a general marker of damage myelinated axons.To test whether CSF NFL associated with cognitive decline and imaging evidence neurodegeneration white matter change in AD.A commercially available immunoassay was used analyze cohort patients AD (n = 95) or mild impairment (MCI) 192) cognitively normal individuals 110)...
Abstract Introduction The Alzheimer's Disease Research Summits of 2012 and 2015 incorporated experts from academia, industry, nonprofit organizations to develop new research directions transform our understanding disease (AD) propel the development critically needed therapies. In response their recommendations, big data at multiple levels are being generated integrated study network failures in disease. We used metabolomics as a global biochemical approach identify peripheral metabolic...
Abstract The heterogeneity of neurodegenerative diseases is a key confound to disease understanding and treatment development, as study cohorts typically include multiple phenotypes on distinct trajectories. Here we introduce machine-learning technique—Subtype Stage Inference (SuStaIn)—able uncover data-driven with temporal progression patterns, from widely available cross-sectional patient studies. Results imaging studies in two reveal subgroups their trajectories regional...
Background The cerebrospinal fluid (CSF) biomarkers amyloid β (Aβ)‐42, total‐tau (T‐tau), and phosphorylated‐tau (P‐tau) demonstrate good diagnostic accuracy for Alzheimer's disease (AD). However, there are large variations in biomarker measurements between studies, within laboratories. Association has initiated a global quality control program to estimate monitor variability of measurements, quantify batch‐to‐batch assay variations, identify sources variability. In this article, we present...
Tau is a hallmark pathology of Alzheimer's disease, and animal models have suggested that tau spreads from cell to through neuronal connections, facilitated by β-amyloid (Aβ). We test this hypothesis in humans using an epidemic spreading model (ESM) simulate spread, compare these simulations observed patterns measured tau-PET 312 individuals along disease continuum. Up 70% the variance overall spatial pattern can be explained our model. Surprisingly, ESM predicts irrespective whether brain...
To investigate the relationship between baseline MRI and CSF biomarkers subsequent change in continuous measures of cognitive functional abilities cognitively normal (CN) subjects patients with amnestic mild impairment (aMCI) Alzheimer disease (AD) to examine ability these predict time conversion from aMCI AD.Data Alzheimer's Disease Neuroimaging Initiative, which consists CN, aMCI, AD cohorts both MRI, were used. Baseline (t-tau, Abeta(1-42), p-tau(181P)) scans obtained 399 (109 192 98 AD)....